HRR Biological Pathways Reviews

Videos

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Videos

Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer

12/12/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 3 of...

12/12/2023

Oncology

Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre

Videos

Prevalence of DNA Repair Defects Among Patients With Metastatic Prostate Cancer

11/02/2023

Featuring Shahneen Sandhu, MBBS

Featuring Shahneen Sandhu, MBBS ...

In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.

In a prospective observational...

11/02/2023

Oncology

Elena Castro, MD, PhD Hospital Universitario 12 de Octubre

Videos

Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations

11/01/2023

Featuring Elena Castro, MD, PhD

Featuring Elena Castro, MD, PhD ...

Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.

Elena Castro, MD, shares final...

11/01/2023

Oncology

Eleni Efstathiou, MD, Houston Methodist Cancer Center

Videos

Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations

02/27/2023

At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...

At 2023 ASCO Genitourinary...

02/27/2023

Oncology

Conference Coverage

The “ABCs” of Immunotherapy for Patients With Acute Myeloid Leukemia

09/06/2024

At the 2024 SOHO meeting, Marion Subklewe, MD, discusses the current landscape and future development of immune and cellular therapies for patients with acute myeloid leukemia.

At the 2024 SOHO meeting, Marion...

09/06/2024

Oncology

Conference Coverage

Challenges of Treating Secondary Acute Myeloid Leukemia With Standard Therapies

09/05/2024

Pinkal Desai, MD discusses the challenges of existing treatment options for patients with secondary acute myeloid leukemia and the need for further development of therapies for this disease subset.

Pinkal Desai, MD discusses the...

09/05/2024

Oncology

Alessandro Santin, MD, Yale Cancer Center

Videos

Efficacy and Safety of Sacituzumab Govetican for Patients With Advanced Endometrial Cancer

09/05/2024

Alessandro Santin, MD, shares insights from the endometrial cancer cohort of the TROPiCS-03 trial, which evaluated sacituzumab govetican among patients with advanced endometrial cancer who have been heavily pretreated.

Alessandro Santin, MD, shares...

09/05/2024

Oncology

Conference Coverage

Developments in Utilizing Interferons for the Treatment of Myeloproliferative Neoplasms

09/04/2024

Abdulraheem Yacoub, MD, shares expert insight into the use of interferons for the treatment of patients with myelofibrosis, essential thrombocythemia, and polycythemia vera.

Abdulraheem Yacoub, MD, shares...

09/04/2024

Oncology

Conference Coverage

Exploring Developments and Challenges of Immunological Approaches in AML Treatment

09/04/2024

At the 2024 Society of Hematologic Oncology meeting, Eduardo Rego, MD, shares his interest in reviewing data on novel research in acute myeloid leukemia treatment development, specifically the incorporation of immunological approaches.

At the 2024 Society of...

09/04/2024

Oncology

Conference Coverage

Analyzing Data on the Improvement of International Outcomes of Acute Myeloid Leukemia Therapy

09/04/2024

Eduardo Rego, MD, shares expert insight into International Consortium on Acute Leukemia research on improving the outcomes of therapy for patients with AML treated in Latin America compared to the outcomes of those treated in the US and...

Eduardo Rego, MD, shares expert...

09/04/2024

Oncology

Videos

Potential for Measurable Residual Disease as an End Point in Chronic Lymphocytic Leukemia Research

09/03/2024

Talal Hilal, MD, discusses an analysis on whether measurable residual disease can serve as a valuable end point in chronic lymphocytic leukemia clinical trials.

Talal Hilal, MD, discusses an...

09/03/2024

Oncology

Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute

Videos

Inavolisib Plus Palbociclib and Fulvestrant for Patients With Relapsed PIK3CA-Mutated Advanced Breast Cancer

09/03/2024

Demetria J. Smith-Graziani , MD, MPH;

Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast...

Demetria Smith-Graziani, MD,...

09/03/2024

Oncology

Videos

Best Management Practices for a Patient With Pediatric Low-Grade Glioma

09/02/2024

Lindsey Hoffman, DO, discusses the course of treatment she would take for a patient with BRAF V600E-mutated pediatric ganglioglioma.

Lindsey Hoffman, DO, discusses...

09/02/2024

Oncology

Videos

Exciting Developments in Chronic Lymphocytic Leukemia Treatment Research

08/28/2024

Matthew Davids, MD, discusses groundbreaking developments in the chronic lymphocytic leukemia treatment landscape, focusing on the latest data from the ongoing AMPLIFY and MAJIC studies.

Matthew Davids, MD, discusses...

08/28/2024

Oncology

News

Conference Coverage

Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations

01/25/2024

Allison Casey

According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...

According to a phase 2 trial,...

01/25/2024

Oncology

News

Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer

10/16/2023

Allison Casey

The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.

The novel, academic-developed...

10/16/2023

Oncology

News

PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer

09/26/2023

Allison Casey

A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.

A quantitative synthesis and...

09/26/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer

09/14/2023

Allison Casey

In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...

In the second interim analysis...

09/14/2023

Oncology

News

Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer

07/26/2023

Stephanie Holland

According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.

According to results from the...

07/26/2023

Oncology

News

Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

06/21/2023

On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.

On June 20, 2023, the US FDA...

06/21/2023

Oncology

News

FDA Approves Olaparib for HRR Gene-Mutated mCRPC

05/20/2020

The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.

The FDA has approved olaparib...

05/20/2020

Oncology

News

Pirtobrutinib Demonstrates Promising Efficacy, Safety Among Patients With B-Cell Malignancies With Richter Transformation

09/06/2024

Amber Denham ;

Pirtobrutinib treatment shows encouraging safety and activity among patients with relapsed/refractory B-cell malignancies who experience Richter transformation, according to a subgroup analysis from the phase 1/2 BRUIN study.

Pirtobrutinib treatment shows...

09/06/2024

Oncology

Conference Coverage

Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer

09/05/2024

Allison Casey ;

According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...

According to updated results...

09/05/2024

Oncology

News

Optimal Trastuzumab Deruxtecan Dose for Patients With HER2-Positive Advanced Colorectal Cancer

09/05/2024

Stephanie Holland ;

According to results from the phase 2 DESTINY-CRC02 trial, 5.4 mg/kg of trastuzumab deruxtecan is preferable to 6.4 mg/kg among patients with HER2-positive metastatic colorectal cancer.

According to results from the...

09/05/2024

Oncology

News

Tarlatamab Sustained Clinical Benefit Among Previously Treated Patients With Small Cell Lung Cancer

09/04/2024

Stephanie Holland ;

According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.

According to extended follow-up...

09/04/2024

Oncology

News

Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission

08/30/2024

Amber Denham ;

According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...

According to results from a...

08/30/2024

Oncology

News

Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma

08/30/2024

Stephanie Holland ;

According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...

According to results from the...

08/30/2024

Oncology

News

Revumenib Demonstrates Clinical Benefit Among Patients With High-Risk, R/R KMT2Ar Acute Leukemia

08/30/2024

Amber Denham ;

According to phase 1/2 results from the AUGMENT study, revumenib, an inhibitor of the menin-lysine methyltransferase 2A interaction, demonstrated high remission rates with a predictable safety profile among patients with relapsed/refractory...

According to phase 1/2 results...

08/30/2024

Oncology

News

Sovleplenib Demonstrates Clinically Meaningful Response Among Patients With Chronic Primary Immune Thrombocytopenia

08/29/2024

Amber Denham ;

Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.

Sovleplenib, a novel spleen...

08/29/2024

Oncology

News

Lymph Node Dissection Improved Overall Survival Among Patients With Stage 3 Endometrial Cancer

08/29/2024

Stephanie Holland ;

According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.

According to results from a...

08/29/2024

Oncology

News

Hearing Loss Among Pediatric Patients with Neurofibromatosis Type 1

08/29/2024

Allison Casey ;

According to a review of audiometric data, the rate of hearing loss among patients with neurofibromatosis type 1 (NF1) compared to the general population was higher than expected.

According to a review of...

08/29/2024

Oncology

Quizzes

Quiz

Efficacy of Revumenib Among Patients With Acute Leukemia

09/06/2024

True or False: According to results from the AUGMENT trial, revumenib demonstrated high remission rates with a predictable safety profile among patients with relapsed/refractory KMT2Ar acute leukemia.TrueFalse

True or False: According to...

09/06/2024

Oncology

Quiz

Well-Being and Quality of Life in Endometrial Cancer

08/28/2024

Do you know which factors can have the greatest impact on psychological well-being and overall quality of life among patients who have undergone surgery for endometrial cancer? Find out with our quiz.

Do you know which factors can...

08/28/2024

Oncology

Quiz

Sacituzumab Govitecan for Patients With Heavily Pretreated Advanced or Metastatic Endometrial Cancer

08/28/2024

Do you know whether sacituzumab govitecan showed promising efficacy among patients with heavily pretreated advanced or metastatic endometrial cancer? Test your knowledge with our quiz.

Do you know whether sacituzumab...

08/28/2024

Oncology

Quiz

Efficacy of Zilurgisertib Alone or Combined With Ruxolitinib in Myelofibrosis

08/22/2024

True or False: According to phase 1/2 results from an ongoing open-label, dose-escalation/expansion study presented at the 2024 European Hematology Association Meeting, zilurgisertib treatment as monotherapy or in combination with ruxolitinib...

True or False: According to...

08/22/2024

Oncology

Quiz

Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer

08/08/2024

Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?

Do you know whether maintenance...

08/08/2024

Oncology

Quiz

08/08/2024

Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...

Based on results from the phase...

08/08/2024

Oncology

Quiz

Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer

08/05/2024

True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...

True or False: According to...

08/05/2024

Oncology

Quiz

Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer

07/15/2024

According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?

According to the final analysis...

07/15/2024

Oncology

Quiz

Ibrutinib Plus Venetoclax For Patients With TP53-Mutated Mantle Cell Lymphoma

07/12/2024

Oncology

Quiz

Weekly Combination Therapy for Patients With R/R Multiple Myeloma

07/11/2024

Oncology

HRR

ALIASES

Human recombination repair

References

Homologous recombination repair (HHR) is a DNA repair mechanism that removes damaged DNA by acting on double-strand breaks, interstrand crosslinks, and other kinds of DNA damage.¹ DNA damage is repaired with high fidelity by correcting damage with information copied from a homologous undamaged molecule.² Defects in HRR are present in some cancers.³

Recent News

Conference Coverage

Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations

01/25/2024

Allison Casey

According to a phase 2 trial,...

01/25/2024

Oncology

News

Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer

10/16/2023

Allison Casey

The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.

The novel, academic-developed...

10/16/2023

Oncology

News

PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer

09/26/2023

Allison Casey

A quantitative synthesis and...

09/26/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer

09/14/2023

Allison Casey

In the second interim analysis...

09/14/2023

Oncology

News

Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer

07/26/2023

Stephanie Holland

According to results from the...

07/26/2023

Oncology

News

Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

06/21/2023

On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.

On June 20, 2023, the US FDA...

06/21/2023

Oncology

News

FDA Approves Olaparib for HRR Gene-Mutated mCRPC

05/20/2020

The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.

The FDA has approved olaparib...

05/20/2020

Oncology

News

Pirtobrutinib Demonstrates Promising Efficacy, Safety Among Patients With B-Cell Malignancies With Richter Transformation

09/06/2024

Amber Denham ;

Pirtobrutinib treatment shows...

09/06/2024

Oncology

Conference Coverage

Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer

09/05/2024

Allison Casey ;

According to updated results...

09/05/2024

Oncology

News

Optimal Trastuzumab Deruxtecan Dose for Patients With HER2-Positive Advanced Colorectal Cancer

09/05/2024

Stephanie Holland ;

According to results from the phase 2 DESTINY-CRC02 trial, 5.4 mg/kg of trastuzumab deruxtecan is preferable to 6.4 mg/kg among patients with HER2-positive metastatic colorectal cancer.

According to results from the...

09/05/2024

Oncology

News

Tarlatamab Sustained Clinical Benefit Among Previously Treated Patients With Small Cell Lung Cancer

09/04/2024

Stephanie Holland ;

According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.

According to extended follow-up...

09/04/2024

Oncology

News

Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission

08/30/2024

Amber Denham ;

According to results from a...

08/30/2024

Oncology

News

Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma

08/30/2024

Stephanie Holland ;

According to results from the...

08/30/2024

Oncology

News

Revumenib Demonstrates Clinical Benefit Among Patients With High-Risk, R/R KMT2Ar Acute Leukemia

08/30/2024

Amber Denham ;

According to phase 1/2 results...

08/30/2024

Oncology

News

Sovleplenib Demonstrates Clinically Meaningful Response Among Patients With Chronic Primary Immune Thrombocytopenia

08/29/2024

Amber Denham ;

Sovleplenib, a novel spleen...

08/29/2024

Oncology

News

Lymph Node Dissection Improved Overall Survival Among Patients With Stage 3 Endometrial Cancer

08/29/2024

Stephanie Holland ;

According to results from a...

08/29/2024

Oncology

News

Hearing Loss Among Pediatric Patients with Neurofibromatosis Type 1

08/29/2024

Allison Casey ;

According to a review of audiometric data, the rate of hearing loss among patients with neurofibromatosis type 1 (NF1) compared to the general population was higher than expected.

According to a review of...

08/29/2024

Oncology